17311002 |
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Meyerson, M,
Thomas, RK,
Wong, KK,
Weir, BA,
Haringsma, HJ,
Lee, JC,
Liniker, E,
Shimamura, T,
Shapiro, GI,
Glatt, KA,
LaFramboise, T,
Minami, Y,
Lowell, AM,
Borgman, CL,
Feng, W,
Wolf, J,
Shah, K
|
Oncogene |
2007 |
16843263 |
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors
Muthuswamy, SK,
Xiang, B,
Gazdar, AF,
Arteaga, CL,
Narasanna, A,
Yang, S,
Carpenter, G,
Perez-Torres, M,
Wu, FY,
Wang, SE
|
Cancer Cell |
2006 |
26182302 |
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies
Ali, SM,
Gay, L,
Morosini, D,
Iwanik, K,
Palmer, G,
Lipson, DM,
Erlich, RL,
Wang, K,
Ross, JS,
Elvin, JA,
Otto, GA,
Rankin, AN,
Stephens, PJ,
Miller, VA,
Chmielecki, J,
Yelensky, R,
White, E
|
JAMA Oncol |
2015 |